首页> The oncologist> Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia.

Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia.

导出 OA

翻译打印收藏纠错

第一作者： Daniel,Lenihan

第一单位： Cardio-Oncology Center of Excellence, Cardiac Rehabilitation, and Heart Failure Clinic, Saint Francis Healthcare System, MO 63703, United States.

作者： Daniel,Lenihan ^[1] ; Michelle,Bloom ^[2] ; Robert,Copeland-Halperin ^[3] ; Matthew R,Fleming ^[4] ; Michael,Fradley ^[5] ; Rupal,O'Quinn ^[6] ; Seema A,Bhat ^[7]

作者单位： Cardio-Oncology Center of Excellence, Cardiac Rehabilitation, and Heart Failure Clinic, Saint Francis Healthcare System, MO 63703, United States. ^[1] Cardio-oncology program, NYU Langone Health, New York, NY 11501, United States. ^[2] Cardiology, Northwell Health, New York, NY 11040, United States. ^[3] Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States. ^[4] Cardio-oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States. ^[5] Cardiovascular Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 43210, United States. ^[6] Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, United States. ^[7]

关键词 Bruton’s tyrosine kinase inhibitor arrhythmia cardiovascular chronic lymphocytic leukemia hemorrhage hypertension